Many different types of drugs are now available to treat multiple myeloma.
While the effectiveness of these treatments is important to managing the disease, it isn’t the only important factor to the patients who take them. Drugs may help treat disease, but they can also have a significant further impact on the way we feel or live our lives.
The aim of this research project is to find out what characteristics of the treatment for relapsed/refractory multiple myeloma (RRMM) are most important to you. This will help better inform future treatment in the context of the needs and preferences of those affected.
The survey is likely to only take you 10-15 minutes. For your time and participation in this study, you will be paid £15.
Thank you for your interest in this research and taking the opportunity to make your voice heard.
You can also be the first to know about the launch of a new clinical trial by signing up to our Research Register.